Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash & Equivalents (2016 - 2025)

Ptc Therapeutics has reported Cash & Equivalents over the past 14 years, most recently at $984.6 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $984.6 million for Q4 2025, up 26.28% from a year ago — trailing twelve months through Dec 2025 was $984.6 million (up 26.28% YoY), and the annual figure for FY2025 was $984.6 million, up 26.28%.
  • Cash & Equivalents for Q4 2025 was $984.6 million at Ptc Therapeutics, up from $672.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PTCT hit a ceiling of $1.5 billion in Q1 2025 and a floor of $104.4 million in Q3 2022.
  • Median Cash & Equivalents over the past 5 years was $244.1 million (2022), compared with a mean of $459.4 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 56.26% in 2021 and later soared 227.39% in 2024.
  • Ptc Therapeutics' Cash & Equivalents stood at $189.7 million in 2021, then surged by 47.5% to $279.8 million in 2022, then skyrocketed by 112.27% to $594.0 million in 2023, then surged by 31.26% to $779.7 million in 2024, then grew by 26.28% to $984.6 million in 2025.
  • The last three reported values for Cash & Equivalents were $984.6 million (Q4 2025), $672.6 million (Q3 2025), and $1.0 billion (Q2 2025) per Business Quant data.